Literature DB >> 33531709

Sixteen novel lineages of SARS-CoV-2 in South Africa.

Houriiyah Tegally1, Eduan Wilkinson1, Richard J Lessells1, Jennifer Giandhari1, Sureshnee Pillay1, Nokukhanya Msomi2, Koleka Mlisana3, Jinal N Bhiman4, Anne von Gottberg4,5, Sibongile Walaza4,6, Vagner Fonseca1, Mushal Allam4, Arshad Ismail4, Allison J Glass5,7, Susan Engelbrecht8, Gert Van Zyl8, Wolfgang Preiser8, Carolyn Williamson9, Francesco Petruccione10,11, Alex Sigal12,13,14, Inbal Gazy1, Diana Hardie9, Nei-Yuan Hsiao9, Darren Martin15, Denis York16, Dominique Goedhals17, Emmanuel James San1, Marta Giovanetti18, José Lourenço19, Luiz Carlos Junior Alcantara18,20, Tulio de Oliveira21,22,23.   

Abstract

The first severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in South Africa was identified on 5 March 2020, and by 26 March the country was in full lockdown (Oxford stringency index of 90)1. Despite the early response, by November 2020, over 785,000 people in South Africa were infected, which accounted for approximately 50% of all known African infections2. In this study, we analyzed 1,365 near whole genomes and report the identification of 16 new lineages of SARS-CoV-2 isolated between 6 March and 26 August 2020. Most of these lineages have unique mutations that have not been identified elsewhere. We also show that three lineages (B.1.1.54, B.1.1.56 and C.1) spread widely in South Africa during the first wave, comprising ~42% of all infections in the country at the time. The newly identified C lineage of SARS-CoV-2, C.1, which has 16 nucleotide mutations as compared with the original Wuhan sequence, including one amino acid change on the spike protein, D614G (ref. 3), was the most geographically widespread lineage in South Africa by the end of August 2020. An early South African-specific lineage, B.1.106, which was identified in April 2020 (ref. 4), became extinct after nosocomial outbreaks were controlled in KwaZulu-Natal Province. Our findings show that genomic surveillance can be implemented on a large scale in Africa to identify new lineages and inform measures to control the spread of SARS-CoV-2. Such genomic surveillance presented in this study has been shown to be crucial in the identification of the 501Y.V2 variant in South Africa in December 2020 (ref. 5).

Entities:  

Mesh:

Year:  2021        PMID: 33531709     DOI: 10.1038/s41591-021-01255-3

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  133 in total

1.  Development of a Platform for Producing Recombinant Protein Components of Epitope Vaccines for the Prevention of COVID-19.

Authors:  Anna S Karyagina; Alexander V Gromov; Tatyana M Grunina; Alexander M Lyaschuk; Alexander V Grishin; Natalia V Strukova; Maria S Generalova; Zoya M Galushkina; Lyubov' A Soboleva; Olga Yu Dobrinina; Tatyana N Bolshakova; Marina E Subbotina; Ekaterina A Romanovskaya-Romanko; Igor V Krasilnikov; Nikita B Polyakov; Andrey I Solovyev; Daniil A Grumov; Vladimir G Zhukhovitsky; Ekaterina I Ryabova; Vladimir V Prokofiev; Vladimir G Lunin
Journal:  Biochemistry (Mosc)       Date:  2021-10       Impact factor: 2.487

Review 2.  A Structural Landscape of Neutralizing Antibodies Against SARS-CoV-2 Receptor Binding Domain.

Authors:  Ling Niu; Kathryn N Wittrock; Gage C Clabaugh; Vikram Srivastava; Michael W Cho
Journal:  Front Immunol       Date:  2021-04-28       Impact factor: 7.561

3.  Epidemiology and genetic diversity of SARS-CoV-2 lineages circulating in Africa.

Authors:  Olayinka Sunday Okoh; Nicholas Israel Nii-Trebi; Abdulrokeeb Jakkari; Tosin Titus Olaniran; Tosin Yetunde Senbadejo; Anna Aba Kafintu-Kwashie; Emmanuel Oluwatobi Dairo; Tajudeen Oladunni Ganiyu; Ifiokakaninyene Ekpo Akaninyene; Louis Odinakaose Ezediuno; Idowu Jesulayomi Adeosun; Michael Asebake Ockiya; Esther Moradeyo Jimah; David J Spiro; Elijah Kolawole Oladipo; Nídia S Trovão
Journal:  medRxiv       Date:  2021-05-19

4.  SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity.

Authors:  Annachiara Rosa; Valerie E Pye; Carl Graham; Luke Muir; Jeffrey Seow; Kevin W Ng; Nicola J Cook; Chloe Rees-Spear; Eleanor Parker; Mariana Silva Dos Santos; Carolina Rosadas; Alberto Susana; Hefin Rhys; Andrea Nans; Laura Masino; Chloe Roustan; Evangelos Christodoulou; Rachel Ulferts; Antoni G Wrobel; Charlotte-Eve Short; Michael Fertleman; Rogier W Sanders; Judith Heaney; Moira Spyer; Svend Kjær; Andy Riddell; Michael H Malim; Rupert Beale; James I MacRae; Graham P Taylor; Eleni Nastouli; Marit J van Gils; Peter B Rosenthal; Massimo Pizzato; Myra O McClure; Richard S Tedder; George Kassiotis; Laura E McCoy; Katie J Doores; Peter Cherepanov
Journal:  Sci Adv       Date:  2021-05-28       Impact factor: 14.136

Review 5.  Fast-spreading SARS-CoV-2 variants: challenges to and new design strategies of COVID-19 vaccines.

Authors:  Weilin Zhou; Wei Wang
Journal:  Signal Transduct Target Ther       Date:  2021-06-09

6.  A Reliable Indirect ELISA Protocol for Detection of Human Antibodies Directed to SARS-CoV-2 NP Protein.

Authors:  Arwa A Faizo; Thamir A Alandijany; Ayman T Abbas; Sayed S Sohrab; Sherif A El-Kafrawy; Ahmed M Tolah; Ahmed M Hassan; Esam I Azhar
Journal:  Diagnostics (Basel)       Date:  2021-05-02

7.  Betacoronaviruses genome analysis reveals evolution toward specific codons usage: Implications for SARS-CoV-2 mitigation strategies.

Authors:  Elisson N Lopes; Vagner Fonseca; Diego Frias; Stephane Tosta; Álvaro Salgado; Ricardo Assunção Vialle; Toscano S Paulo Eduardo; Fernanda K Barreto; Vasco Ariston de Azevedo; Michele Guarino; Silvia Angeletti; Massimo Ciccozzi; Luiz C Junior Alcantara; Marta Giovanetti
Journal:  J Med Virol       Date:  2021-05-24       Impact factor: 20.693

8.  Strategic testing approaches for targeted disease monitoring can be used to inform pandemic decision-making.

Authors:  James D Nichols; Tiffany L Bogich; Emily Howerton; Ottar N Bjørnstad; Rebecca K Borchering; Matthew Ferrari; Murali Haran; Christopher Jewell; Kim M Pepin; William J M Probert; Juliet R C Pulliam; Michael C Runge; Michael Tildesley; Cécile Viboud; Katriona Shea
Journal:  PLoS Biol       Date:  2021-06-17       Impact factor: 8.029

9.  Intranasal plus subcutaneous prime vaccination with a dual antigen COVID-19 vaccine elicits T-cell and antibody responses in mice.

Authors:  Adrian Rice; Mohit Verma; Annie Shin; Lise Zakin; Peter Sieling; Shiho Tanaka; Joseph Balint; Kyle Dinkins; Helty Adisetiyo; Brett Morimoto; Wendy Higashide; C Anders Olson; Shivani Mody; Patricia Spilman; Elizabeth Gabitzsch; Jeffrey T Safrit; Shahrooz Rabizadeh; Kayvan Niazi; Patrick Soon-Shiong
Journal:  Sci Rep       Date:  2021-07-21       Impact factor: 4.379

10.  A Comprehensive Molecular Epidemiological Analysis of SARS-CoV-2 Infection in Cyprus from April 2020 to January 2021: Evidence of a Highly Polyphyletic and Evolving Epidemic.

Authors:  Andreas C Chrysostomou; Bram Vrancken; George Koumbaris; George Themistokleous; Antonia Aristokleous; Christina Masia; Christina Eleftheriou; Costakis Iοannou; Dora C Stylianou; Marios Ioannides; Panagiotis Petrou; Vasilis Georgiou; Amalia Hatziyianni; Philippe Lemey; Anne-Mieke Vandamme; Philippos P Patsalis; Leondios G Kostrikis
Journal:  Viruses       Date:  2021-06-09       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.